Compounds

1. A compound of Formula (I) or pharmaceutically acceptable salt thereof

wherein

n is 1 or 2;

R 1 is hydrogen, fluoro, methyl or methoxy; and

R 2 is phenyl, pyridyl, C 3-6 cycloalkyl, piperidin-1-yl or tetrahydropyranyl, wherein phenyl and pyridyl are optionally substituted by one to three substituents independently selected from chloro, fluoro, cyano, C 1-3 alkyl optionally substituted by one or more fluoro, or C 1-3 alkoxy optionally substituted by one or more fluoro, and cycloalkyl, piperidin-1-yl and tetrahydropyranyl are optionally substituted by one or two fluoro.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein n is 1.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is hydrogen.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is phenyl, pyridyl or C 3-6 cycloalkyl,

wherein phenyl and pyridyl are optionally substituted by one to three substituents independently selected from chloro, fluoro, methyl optionally substituted by one or more fluoro, or methoxy substituted by one or more fluoro, and cycloalkyl is unsubstituted.

5. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is phenyl, pyridyl or C 3-6 cycloalkyl,

wherein phenyl and pyridyl are optionally substituted by one to three substituents independently selected from chloro, fluoro, methyl, trifluoromethyl, methoxy or trifluoromethoxy, and cycloalkyl is unsubstituted.

6. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is phenyl, pyridyl or C 3-6 cycloalkyl,

wherein phenyl and pyridyl are optionally substituted by one to three substituents independently selected from chloro and fluoro, and cycloalkyl is unsubstituted.

7. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is fluoro, methyl or methoxy.

8. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is phenyl optionally substituted by one to three substituents independently selected from chloro, fluoro, cyano, C 1-3 alkyl optionally substituted by one or more fluoro, or C 1-3 alkoxy optionally substituted by one or more fluoro.

9. The compound or pharmaceutically acceptable salt thereof according to claim 8 , wherein R 2 is phenyl optionally substituted by one fluoro.

10. The compound or pharmaceutically acceptable salt thereof according to claim 1 selected from:

4,4,4-trifluoro-1-[3-(4-fluorophenyl)azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-[3-(trifluoromethyl)phenyl]azetidin-1-yl]butan-1-one;

5,5,5-trifluoro-1-[3-(4-fluorophenyl)azetidin-1-yl]pentan-1-one;

1-(3-cyclopropylazetidin-1-yl)-4,4,4-trifluoro-butan-1-one;

1-(3-cyclopentylazetidin-1-yl)-4,4,4-trifluoro-butan-1-one;

1-(3-cyclohexylazetidin-1-yl)-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-[4-(trifluoromethyl)-2-pyridyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-[5-(trifluoromethyl)-2-pyridyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(5-fluoro-2-pyridyl)azetidin-1-yl]butan-1-one;

1-[3-(3,5-difluoro-2-pyridyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

1-[3-(4-chloro-2-pyridyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-[2-(trifluoromethyl)-4-pyridyl]azetidin-1-yl]butan-1-one;

1-[3-(4-chlorophenyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-[4-(trifluoromethoxy)phenyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-[3-(trifluoromethoxy)phenyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-[4-(trifluoromethoxy)phenyl]azetidin-1-yl]butan-1-one;

1-[3-(3-chlorophenyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

1-[3-(2,4-difluorophenyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

1-[3-(2,4-difluorophenyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

1-[3-(2-chloro-4-fluoro-phenyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-[6-(trifluoromethyl)-3-pyridyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(6-methoxy-3-pyridyl)azetidin-1-yl]butan-1-one;

1-[3-(5-chloro-3-pyridyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-[5-(trifluoromethyl)-3-pyridyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-[4-fluoro-2-(trifluoromethyl)phenyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(3-pyridyl)azetidin-1-yl]butan-1-one;

1-[3-(3,4-difluorophenyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-(4-fluoro-2-methyl-phenyl)azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(3-fluorophenyl)azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(4-pyridyl)azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(2-fluoro-4-pyridyl)azetidin-1-yl]butan-1-one;

1-[3-(2-chloro-4-pyridyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-(6-fluoro-3-pyridyl)azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-(3,4,5-trifluorophenyl)azetidin-1-yl]butan-1-one;

1-[3-(4,4-difluoro-1-piperidyl)azetidin-1-yl]-4,4,4-trifluoro-butan-1-one;

4,4,4-trifluoro-1-[3-(6-isopropoxy-3-pyridyl)azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridyl]azetidin-1-yl]butan-1-one;

4,4,4-trifluoro-1-(3-(tetrahydro-2H-pyran-4-yl)azetidin-1-yl)butan-1-one;

1-(3-(4,4-difluorocyclohexyl)azetidin-1-yl)-4,4,4-trifluorobutan-1-one;

4,4,4-trifluoro-1-(3-(piperidin-1-yl)azetidin-1-yl)butan-1-one;

4,4,4-trifluoro-1-(3-(4-fluorophenyl)-3-methoxyazetidin-1-yl)butan-1-one;

4,4,4-trifluoro-1-(3-(4-fluorophenyl)-3-methylazetidin-1-yl)butan-1-one;

4-(1-(4,4,4-trifluorobutanoyl)azetidin-3-yl)benzonitrile; and

4,4,4-trifluoro-1-(3-fluoro-3-(4-fluorophenyl)azetidin-1-yl)butan-1-one.

11. The method for the treatment of a mycobacterial infection in a human in need thereof, comprising administering to said human a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .

12. A method for the treatment of a disease caused by infection with a Mycobacterium in a human in need thereof, comprising administering to said human a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .

13. A pharmaceutical composition comprising (a) a compound or pharmaceutically acceptable salt thereof according to claim 1 ; and (b) a pharmaceutically acceptable excipient.

14. A combination of (a) the compound or pharmaceutically acceptable according to claim 1 and (b) at least one other anti-mycobacterial agent.

15. The combination according to claim 14 , wherein the at least one other anti-mycobacterial agent is an anti-tuberculosis agent.

16. The combination according to claim 15 , wherein the anti-tuberculosis agent is selected from isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin, rifapentine, clofazimine, ethionamide, prothionamide, isoxyl, thiacetazone, rifabutin, a diarylquinoline, nitroimidazo-oxazine PA-824, delamanid (OPC-67683), an oxazolidinone, EMB analogue SQ109, OPC-167832, GSK3036656 (also known as GSK070), GSK2556286, GSK3211830, a benzothiazinone, an azaindole, a dinitrobenzamide, and a beta-lactam, or beta-lactam combinations.

17. The combination according to claim 14 , further comprising an antiviral agent.

18. The combination according to claim 17 , wherein the antiretroviral agent is selected from zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, oltipraz, capravirine, lersivirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, GSK1349572, GSK1265744, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, and darunavir.

19. A method for the treatment of tuberculosis in a human in need thereof, comprising administering to said human a therapeutically effective amount the compound, or pharmaceutically acceptable salt thereof according to claim 1 .

20. The method according to claim 11 , wherein the mycobacterial infection is a Mycobacterium tuberculosis infection.

21. The method according to claim 12 , wherein the disease caused by infection with a Mycobacterium is a Mycobacterium tuberculosis infection.

22. A method for the treatment of a mycobacterial infection in a human in need thereof, comprising administering to said human (a) the compound or pharmaceutically acceptable salt thereof according to claim 1 ; and (b) at least one other anti-mycobacterial agent.

23. The method according to claim 22 , wherein the at least one other anti-mycobacterial agent is an anti-tuberculosis agent.

24. The method according to claim 23 , wherein the anti-tuberculosis agent is selected from isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin, rifapentine, clofazimine, ethionamide, prothionamide, isoxyl, thiacetazone, a diarylquinoline, nitroimidazo-oxazine PA-824 (pretomanid), delamanid (OPC-67683), an oxazolidinone, EMB analogue SQ109, OPC-167832, GSK3036656A (also known as GSK070), GSK2556286, GSK3211830, a benzothiazinone, an azaindole, a dinitrobenzamide, and a beta-lactam, or beta-lactam combinations.

25. The method according to claim 22 , further comprising an antiviral agent.

26. The method according to claim 25 , wherein the antiretroviral agent is selected from zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, oltipraz, capravirine, lersivirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, GSK1349572, GSK1265744, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, and darunavir.